Domestic and foreign scholars are exploring various combination therapies such as PD-1/PD-L1 inhibitors, VEGF inhibitors, and multi-target kinase inhibitors, with the aim of lifting the immune suppression in the tumor microenvironment. The gene discussed is VEGFA; the disease is neoplasm.